There are high levels of variation between Strategic Health Authorities and Primacy Care Trusts in the uptake of new drugs, …
NICE has published updated final guidance on preventing osteoporotic fractures following a reconsideration of the use of Servier’s Protelos. The …
A leading health economist has questioned claims by the health secretary Andrew Lansley that England’s health is lagging behind other …

Pfizer has expanded its use of Twitter with its French operations becoming the latest of its European subsidiaries to join …
Almirall has appointed Bertil Lindmark as executive director of R&D following the retirement of Dr Per-Olof Andersson. Bertil joins the …
Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced …
Novartis has posted strong sales growth for the full year but its chief executive warns of ‘headwinds in 2011’ as …
Prime Minister David Cameron has made exclusive use of Doctors.net.uk, the UK’s largest network of medical professionals, to reinforce his …
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
Double Helix Consulting has appointed three new executives to its growing global team – Clara Loveman, Dr Clive Whitcher and …
The regulatory landscape can change in a very short period of time. Matthew Walker, Senior Regulatory Affairs Executive at TRAC …
Research and development partnerships between big pharma and the biotech sector are now a vital component in bringing new medicines …
Sanofi-Aventis has bought a global licence to develop and commercialise one of Oxford BioTherapeutics’ (OBT) oncology programmes. For an undisclosed …
Falling fourth quarter sales of Risperdal Consta and Remicade capped a year to forget for Johnson and Johnson. The company’s …
German clinical research company AiCuris has appointed Dr Marie-Paule Richard as chief medical officer. She has over 24 years of …
A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …
The government has pledged that value-based competition in the NHS will create “the very opposite of the postcode lottery”, following …

Amgen is set to pay $1 billion for US biotech firm BioVex, in the process gaining access to its novel …
Chemical distributor Univar has promoted David Jukes to president of its European operations. He replaces John van Osch who is …
US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …